Back to Search Start Over

Cyclic boronates as versatile scaffolds for KPC-2 β-lactamase inhibitionElectronic supplementary information (ESI) available: Supplemental figures and tables. See DOI: 10.1039/c9md00557a

Authors :
Tooke, Catherine L.
Hinchliffe, Philip
Krajnc, Alen
Mulholland, Adrian J.
Brem, Jürgen
Schofield, Christopher J.
Spencer, James
Source :
MedChemComm; 2020, Vol. 11 Issue: 4 p491-496, 6p
Publication Year :
2020

Abstract

Klebsiella pneumoniaecarbapenemase-2 (KPC-2) is a serine-β-lactamase (SBL) capable of hydrolysing almost all β-lactam antibiotics. We compare KPC-2 inhibition by vaborbactam, a clinically-approved monocyclic boronate, and VNRX-5133 (taniborbactam), a bicyclic boronate in late-stage clinical development. Vaborbactam inhibition is slowly reversible, whereas taniborbactam has an off-rate indicating essentially irreversible complex formation and a 15-fold higher on-rate, although both potentiate β-lactam activity against KPC-2-expressing K. pneumoniae. High resolution X-ray crystal structures reveal closely related binding modes for both inhibitors to KPC-2, with differences apparent only in positioning of the endocyclic boronate ester oxygen. The results indicate the bicyclic boronate scaffold as both an efficient, long-lasting, KPC-2 inhibitor and capable of supporting further iterations that may improve potency against specific enzyme targets and pre-empt the emergence of inhibitor resistant KPC-2 variants.

Details

Language :
English
ISSN :
20402503 and 20402511
Volume :
11
Issue :
4
Database :
Supplemental Index
Journal :
MedChemComm
Publication Type :
Periodical
Accession number :
ejs53114145
Full Text :
https://doi.org/10.1039/c9md00557a